Navigation Links
Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R)
Date:8/11/2009

KENILWORTH, N.J., Aug. 11 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus Pharma, Inc. ("Orchid"), related to the generic manufacturing of certain formulations of CLARINEX(R) (desloratadine).

The agreement marks the end of all pending litigations filed and consolidated since 2006 in the U.S. District Court for the District of New Jersey against several generic drug manufacturing companies that had sought approval to market solid oral dosage forms of desloratadine products in the United States as generic brands prior to the expiration of certain Schering Corporation patents.

This agreement resolves all pending patent infringement litigation filed by Schering Corp. against Orchid and will allow Orchid to introduce a generic version of the CLARINEX(R) brand REDITABS (orally-disintegrating tablets) to be introduced into the U.S. market on January 1, 2012, and CLARINEX(R) brand 5 milligram tablets to be introduced on July 1, 2012. Schering holds various patents related to CLARINEX(R) that extend to 2022.

Beginning in September of 2006, Schering Corp. filed complaints for patent infringement against generic drug manufacturing companies that sought U.S. marketing rights for generic versions of CLARINEX tablets, CLARINEX REDITABS and/or CLARINEX-D12/-D 24 Extended Release Tablets. Since then, consent orders have been entered and/or settlements now have been reached in the cases against Anchen Pharmaceuticals, Inc., Belcher Pharmaceuticals, Inc., Caraco Pharmaceutical Laboratories, Ltd., Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd., GeoPharma, Inc., Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals, Ltd., Lupin Pharmaceuticals, Inc. and Lupin Ltd., Myla
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Schering-Plough to Webcast Special Meeting of Shareholders
2. Schering-Plough Reports Proposed Settlement in Litigation Involving Planned Merger with Merck
3. New Vaccine from Intervet/Schering-Plough Animal Health is First for Canine Influenza Virus
4. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
5. Valeant Grants Schering-Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal
6. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
7. Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males
8. Schering-Plough Starts Patient Enrollment in Phase 3 Trial for Acadesine, an Investigational Agent Being Studied for Prevention of Complications From Cardiac Surgery
9. Schering-Plough Flips the Switch on 1.7 MW Rooftop Solar Panel System, One of the Largest in N.J., North America
10. J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards
11. Schering-Plough Reports Financial Results for 2009 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014)A diet rich in soy may help feminine hearts, ... today in Menopause , the journal of The ... to the diet of women in Asia, produces the ... similar to Asian migrants to North America, leads to ... and switching to soy from a Western diet after ...
(Date:7/29/2014)... July 29, 2014 Daily Gossip indicates in ... method was created for any sufferer who is looking for ... The author of the new program, Sarah Summer, says that ... suffered from yeast infection, too. Actually, this is the reason ... this problem. , The Natural Cure for Yeast ...
(Date:7/29/2014)... Port Washington, New York (PRWEB) July 29, 2014 ... dedicated to protecting the rights of victims injured by ... action lawsuit has been filed by plaintiffs in Canada ... increased risk of cardiovascular events with the low ... was filed on July 22, 2014 in the Ontario ...
(Date:7/29/2014)... Regardless of the good things that ... to share those with. Love is about understanding, commitment ... Love is also about overcoming all the challenges that ... perfect relationship, women need to know how to understand ... Him program, please visit the official website at ...
(Date:7/29/2014)... of severe combat injuries threatening more than one limb, ... record of safety and effectiveness in avoiding amputation, reports ... Plastic and Reconstructive Surgery , the official medical ... (ASPS). , Experience with multiple limb salvage procedures ... success rates, with no increase in complications compared to ...
Breaking Medicine News(10 mins):Health News:Soy may help women's hearts if they start early 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 2Health News:Class Action Lawsuit in Canada Alleges Manufacturer of Delatestryl Testosterone Injection Failed to Warn of Cardiovascular Risks, Parker Waichman LLP Reports 3Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Good outcomes with multiple limb salvage after severe combat injuries, reports Plastic and Reconstructive Surgery 2
... TALLAHASSEE, Fla., Aug. 12 With the recent increase in ... in these already hard economic times - do they pay the ... those who want to quit, The Florida Quitline (1-877-U-CAN-NOW) is here ... , , According to Kim Berfield, Deputy Secretary ...
... , , , , ... a leading provider of Linux-bas e d ... Systems, a national health care management company, has deployed Arkeia Network Backup. ... Goold has realized dramatic improvements in backup performance and in backup administration. ...
... Fountain Healthy Aging,Inc. announced on August 12 2009 that ... Oak Resources Limited which provides the Company,with a $5,000,000 Equity ... has the right to draw down from the Equity Line,Investment ... of 24 months. The,first tranche investment of $1,000,000 was drawn ...
... , WESTFIELD, Ind., Aug. 12 maxIT ... healthcare providers, announced the successful "Stage 6" designation of Gila ... in Silver City, New Mexico. maxIT assisted the Phoenix Health ... to support the implementation of several HIS modules. Beginning ...
... , , , ... (NYSE: HI ) -- Hillenbrand, Inc. reported net revenues of ... 2009, a $6.3 million (3.8 percent) decline from the same period in ... million (4.9 percent) decline. The difference in as-adjusted net income for the ...
... , , , ... create expensive home health care costs. Poorly designed mobility aids or ... issue only part of the need is addressed which creates mobility ... alleviated if mobility issues were detected and properly addressed. , ...
Cached Medicine News:Health News:The Time To Quit Is Now -- Free NRT Is Available 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 2Health News:Goold Health Systems Accelerates Backups by 5-times Using Arkeia Network Backup 3Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 2Health News:Fountain Healthy Aging Inc Announces $5,000,000 Equity Line Of Credit Investment Secured 3Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 2Health News:maxIT Assists Medical Center to Achieve Prestigious Stage 6 Recognition 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 2Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 3Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 4Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 5Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 6Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 7Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 8Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 9Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 10Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 11Health News:Hillenbrand Reports 2.4% Decline in Earnings Per Share on 3.8% Lower Revenues in Third Quarter 2009 12Health News:Expensive Health Care: Undetected, Unmet Mobility Needs Creating Boomer & Senior Health Care Costs 2
(Date:7/29/2014)...  EnteroMedics Inc. (NASDAQ: ETRM ), the ... obesity, metabolic diseases and other gastrointestinal disorders, today announced ... August 7, 2014 at 11:00 AM Eastern Time to ... 30, 2014 and to provide a business update. ... conference call may be accessed by dialing (877) 280-7473 ...
(Date:7/29/2014)... 29, 2014 New high priced hepatitis C ... by a projected $2.9 to $5.8 billion next year, ... Milliman released today by the Pharmaceutical Care Management Association ... increase by as much as 8.6 percent in 2015 ... Sovaldi and Olysio. The study finds that ...
(Date:7/29/2014)... and NEW YORK , ... of the executive management team of Caremark Rx, ... Media ( www.pbm365.com ).  PBM365 is the leading independent ... reporting, insight, analysis and opinion on the pharmacy ... will provide insightful and timely coverage of, and context ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 2EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call 3New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Drew Crawford Announces Launch of PBM365 Media 2
... Test builds on company,s suite of tests to ... Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing ... new diagnostic assay designed to help physicians better ... infections. The company will introduce the Pneumococcal ...
... of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI ... Given With Standard Platelet TherapyKENILWORTH, N.J., March 12 ... ) Phase II trial of SCH 530348, a novel ... The Lancet and demonstrated that the investigational ...
Cached Medicine Technology:IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 2Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 3Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 4Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 5Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 6Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study 7
Provides quick freezing and quick defrosting. Lightweight probe tips have high conductivity silver. Useful for Cataract, Retinal Detachment, Glaucoma and Intra-vitreal surgery. Includes either one ca...
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... planned ECCE with peristaltic pump with ... suction, reflux possible with multi-function footswitch ... all critical functions. You can also ... actual vacuum level indicated by Bar ...
Medicine Products: